---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-002644"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:47:56.002174+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CEO William Febbo departs OptimizeRx; receives $675K salary continuation + $450K bonus

## Summary
- William J. Febbo stepped down as CEO and Board member effective Dec 31, 2024; separation agreement signed Jan 3, 2025.
- Severance includes $450k/yr base salary for 18 months ($675k total) and a lump-sum $450k bonus.
- COBRA premium reimbursement for 12 months; advisory services through March 31, 2025 with continued equity vesting.
- 12-month non-compete and non-solicit obligations apply; no replacement CEO named yet.
- Equity awards continue to vest during the 3-month advisory period.

## SEC filing metadata
- accession: 0001213900-25-002644
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/0001213900-25-002644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/ea0227345-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-002644
- JSON: https://secwatch.observer/filing/0001213900-25-002644.json
- Plain text: https://secwatch.observer/filing/0001213900-25-002644.txt

## Key facts
- Executive change
  William J. Febbo departed as Chief Executive Officer at OptimizeRx Corp.
  - Action: stepped down
  - Role: Chief Executive Officer
  source text: William J. Febbo stepped down from his positions as Chief Executive Officer (“CEO”) and Member of the Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”) effective as of December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/0001213900-25-002644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.